Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.75 |
| ▸ | MAPT | P10636 | 8/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.75 |
| ▸ | USP2 | O75604 | 4/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.75 |
| ▸ | TP53 | P04637 | 4/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ODC1 | P11926 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | GALR3 | O60755 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11938548 | 1.00 | CYP3A4 (0.75) | CYP3A4SMN1; SMN2MAPTTDP1KDM4E | |
| SCHEMBL13557430 | 0.91 | CYP3A4 (0.66) | CYP3A4SMN1; SMN2MAPTTDP1KDM4E | |
| SCHEMBL13557428 | 0.91 | CYP3A4 (0.66) | CYP3A4SMN1; SMN2MAPTTDP1KDM4E | |
| SCHEMBL11938549 | 0.86 | CYP3A4 (0.80) | CYP3A4SMN1; SMN2MAPTTDP1KDM4E | |
| SCHEMBL11938491 | 0.86 | CYP3A4 (0.80) | CYP3A4SMN1; SMN2MAPTTDP1KDM4E | |
| Toxicarol SCHEMBL25199717 | 0.86 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTDP1KDM4E | |
| Toxicarol SCHEMBL4742046 | 0.86 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTDP1KDM4E | |
| SCHEMBL14273346 | 0.86 | CYP3A4 (0.80) | CYP3A4SMN1; SMN2MAPTTDP1KDM4E | |
| SCHEMBL19185964 | 0.86 | CYP3A4 (0.80) | CYP3A4SMN1; SMN2MAPTTDP1KDM4E | |
| SCHEMBL11938552 | 0.85 | CYP3A4 (0.69) | CYP3A4SMN1; SMN2MAPTTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718786-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160130235-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| US-9161997-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. | 2015-10-20 | — | — | US | disclosed |
| US-8226929-B2 | Administering to a patient a contrast agent (pyridimifen, fenazaquin) which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-7344702-B2 | Contrast agents for myocardial perfusion imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | CYP3A4 3831/4885SMN1; SMN2 2969/4885MAPT 4043/4885 |
| US-20160130235-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | CYP3A4 3831/4885SMN1; SMN2 2969/4885MAPT 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.